Join
Live feed
·
PRReleasevia Quantisnow
Abivax SA logo

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

ByQuantisnow·Wall Street's wire, on your screen.
ABVX· Abivax SA
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABVX (Abivax SA) and more on Quantisnow.